AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Istituto Nazionale dei Tumori, M…
💬

In plain words

What the trial is, and whether it could suit you

Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic and predictive factors are lacking and many questions are still open on the optimal management. In the context of EURACAN, a prospective registry specifically dedicated to EHE was developed and launched with the aim of providing, through high-quality prospective data collection, a better understanding of this disease. The study design is a registry-based cohort study including only new cases of patients with a pathological and molecularly confirmed diagnosis of EHE. The objectives are to improve the understanding of EHE natural history, validate and identify new prognostic and predictive factors, clarify the activity and efficacy of currently available trea

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * New patients managed by the contributing centers with a pathological EHE diagnosis performed or verified by an expert sarcoma pathologist starting from 1 December 2023 onwards and to be performed within 6 months from the registration * Molecular confirmation of the diagnosis (WWTR1-CAMTA1 or YAP1-TFE3) * Adult patients (aged ≥ 18 years)
💊

What it tests

  • Not listed
📍

Where

22 sites
University Hospital Graz
Graz, Austria
Aarhus University Hospital
Aarhus, Denmark
Léon Bérard Center
Lyon, France
Centre Oscar Lambret
Lille, France
Essen University Hospital
Essen, Germany
Campus Großhadern
München, Germany
Istituto Ortopedico Rizzoli
Bologna, Italy
Azienda Ospedaliero Universitaria Careggi
Careggi, Italy

…and 14 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy